This decision shows that it may be useful to appeal a refusal of an application, and show that the initial closest prior art in an inventive step rejection should actually not have been considered to be the closest prior art. Starting from another closest prior art document, the result here was that the appeal board came to different conclusion than the examining division (and in fact agreed with the applicant).
Besides that, for readers that may struggle with the meaning of blood, blood-based sample, blood sample, serum sample, plasma sample, blood-derived sample, etc., this decision clarifies that one can never be too careful in describing in the application as filed what samples are being used, since these terms are certainly not readily exchangeable. The components in blood are multifold and endless different kinds of blood-based samples may possibly be used, according to the board.
Summary of Facts and Submissions
I. The appeal lies from the decision of the Examining Division announced at oral proceedings on 1 December 2010 refusing European patent application No. 07 754 043.3.
Claim 1 of the application as originally filed read as follows:
"1. A method of determining whether a patient will be responsive to a drug or treatment, the method comprising:
obtaining a test spectrum produced by a mass spectrometer from a serum produced from a patient having a disease;
processing the test spectrum to determine a relation to a group of class labeled spectra produced from respective serum from other patients having a same or similar clinical stage disease and known to have responded to or not responded to a drug or treatment; and
determining, based on the relation of the test spectrum to the group of class labeled spectra, whether the patient will be responsive to the drug or treatment."